Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,
Keywords: imaging criteria, response evaluation, CT scan,
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Dromain C, Majdi A, Houchard A,
Keywords: Lanreotide, dosing interval,
Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Dromain C
Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: De Martino M, Ducreux M, Dromain C, Duvillard P, Guigay J, Leboulleux S,
Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor,